American ginseng berry juice intake reduces blood glucose and body weight in ob/ob mice.
Diabetes is a serious chronic metabolic disease and has a significant impact on patients' lives and the health care system. We previously observed that the organic solvent extract of American ginseng berry possessed significant antidiabetic effects in obese diabetic ob/ob mice after intraperitoneal injection. If American ginseng berry is useful as a dietary supplement, simple preparation and oral intake would be a convenient, safe, and practical means for consumers. In this study, the simply prepared berry juice was first analyzed using high-performance liquid chromatography, and then administered orally in the ob/ob mice. The animals received daily berry juice 0.6 mL/kg or vehicle for 10 consecutive days. The results indicated that oral juice administration significantly lowered fasting blood glucose levels, and this effect continued for at least 10 d after cessation of the treatment. Data from intraperitoneal glucose tolerance test demonstrated that there was a notable improvement in glucose tolerance in the juice treated group. In addition, the berry juice significantly reduced body weight. Our data suggest that ginseng berry juice, as a dietary supplement, may have functional efficacy in consumers with diabetes.
Xie
J T
JT
Tang Center for Herbal Medicine Research, Committee on Clinical Pharmacology and Pharmacogenomics, and Dept. of Anesthesia & Critical Care, The Pritzker School of Medicine, Univ. of Chicago, Chicago, IL 60637, USA.
Wang
C Z
CZ
Ni
M
M
Wu
J A
JA
Mehendale
S R
SR
Aung
H H
HH
Foo
A
A
Yuan
C S
CS
D000284:Administration, Oral; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001628:Beverages / Q000032:analysis*; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects*; D002851:Chromatography, High Pressure Liquid; D019587:Dietary Supplements; D036145:Ginsenosides / Q000008:administration & dosage* / Q000627:therapeutic use; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008820:Mice, Obese; D009753:Nutritive Value; D005894:Panax / Q000737:chemistry*; D011897:Random Allocation; D013997:Time Factors
D019440:Anti-Obesity Agents; D001786:Blood Glucose; D036145:Ginsenosides; D007004:Hypoglycemic Agents